Who we are
Meddenovo Drug Design is a Lyon-based biotech company developing advanced computational technologies for peptide drug discovery. At the intersection of artificial intelligence, physics-based modeling, and molecular design, we enable the discovery of next-generation peptide therapeutics in collaboration with industrial partners.
What we do
We develop Mexa, an AI-powered platform for the de novo design of cyclic peptides. Mexa explores tens of millions of candidates per target, combining large-scale AI-driven generation with physics-based evaluation and refinement. It can initiate discovery without prior experimental data, enabling rapid hit identification across internal and partnered programs.
Our value proposition
Meddenovo designs viable cyclic peptide drug candidates from scratch, even in the absence of existing leads. By combining broad chemical space exploration with rigorous biophysical validation, Mexa delivers high-quality, target-specific hits within short timelines. This approach reduces early discovery risk and unlocks peptide-based modalities for challenging targets, particularly in oncology, radiopharmaceuticals, and metabolic diseases.
Cyclic peptides occupy a unique space between small molecules and biologics. Their structural rigidity enables strong, selective target binding, while their size and versatility allow them to access complex biological interfaces beyond the reach of traditional drugs. This positions cyclic peptides as a high-potential modality for the next generation of therapeutics.
